347187-35-3

Usage

Uses

Used in Pharmaceutical Industry:
(3-acetylamino-phenyl)acetic acid methyl ester is used as an intermediate in the synthesis of nonsteroidal anti-inflammatory drugs (NSAIDs) and other medicinal products. Its role in the production of these drugs is crucial due to its ability to facilitate the creation of compounds that can effectively manage inflammation and pain.
Used in Research and Development:
(3-acetylamino-phenyl)acetic acid methyl ester also has potential applications in research and development. Its structural and functional properties make it a valuable compound for exploring new avenues in chemical and pharmaceutical research, potentially leading to the discovery of novel applications and products.

Upstream product

• 52913-11-8 (3-amino-phenyl)-acetic acid methyl ester 
• 108-24-7 acetic anhydride 
• 626-01-7 3-Iodoaniline 
• 19230-45-6 N-(3-iodophenyl)acetamide 
• 292638-85-8 acrylic acid methyl ester 
• 1877-73-2 3-nitro-benzeneacetic acid 
• 10268-12-9 methyl 3-nitrophenylacetate 
• 75-36-5 acetyl chloride 
• 14338-36-4 3-amino phenylacetic acid 
• 60-35-5 acetamide 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 1878-67-7 3-Bromophenylacetic acid 

Downstream Products

• 603108-66-3 methyl 2-(3-(ethylamino)phenyl)acetate 
• 37777-54-1 (3-acetylamino-phenyl)acetic acid 

Relevant academic research and scientific papers

Pyridineacetamide derivative serving as CDK inhibitor, and preparation method and application thereof

The invention belongs to the technical field of pyridineacetamide derivatives, and particularly relates to a pyridineacetamide derivative serving as a CDK inhibitor and a preparation method and application of the pyridine acetamide derivative. The pyridineacetamide derivative shows excellent CDK9/CDK7 enzyme inhibitory activity, and can be used for preparing drugs used for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors such as breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

BORONIC ACID DERIVATIVES

Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmue disorder abnomality or hematological malignancies.

Ti/Ni-mediated inter- and intramolecular conjugate addition of aryl and alkenyl halides and triflates

In this work, we show that the unique combination of a nickel catalyst and Cp2TiCl allows the direct conjugate addition of aryl and alkenyl iodides, bromides, and to a lesser extent, chlorides and triflates to α,β-unsaturated carbonyls at room temperature, without requiring the previous formation of an organometallic nucleophile. The reaction proceeds inter- and intramolecularly with good functional group compatibility, which is key for the development of free protecting group methodologies. Carbo- and heterocycles of five- and six-membered rings are obtained in good yields. Moreover, some insights about the mechanism involved have been obtained from cyclic voltammetry, UV-vis, and HRTEM measurements.

Design and synthesis of new prostaglandin D2 receptor antagonists

To identify new cost-effective prostaglandin D2 (DP) receptor antagonists, a series of novel 3-benzoylaminophenylacetic acids were synthesized and biologically evaluated. Among those tested, some representative compounds were found to be orally

CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT

A carboxylic acid compound represented by formula (I): (meanings of the symbols in the formula are as mentioned in the specification) and a pharmaceutical agent comprising the compound. Since the compound represented by formula (I) binds to a DP receptor and shows antagonistic activity for the DP receptor, it is useful for prevention and/or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.